Team:Uppsala University/Project

Antibiotic resistance is a major global health problem. During the last couple of decades, antibiotic resistance has become increasingly problematic, and there is no doubt that new approaches to solve this problem at a technical level are needed to alleviate the problem. The data below is taken from the european center for disease prevention and control (ECDC) and shows the proportion of resistant isolates of Klebsiella pneumoniae in the member states of the European Union from 2000 to 2010.

Misuse and overuse of antibiotics are contributing factors to the severity of the problem, and it seems that we need new approaches to solve it.

One approach to the problem is to keep developing new kinds of antibiotics, but unfortunately there is no certainty that we can keep up with the resistance development. We are fighting a never ending battle against bacterial evolution that we at the moment seem to be losing. An outside-the-box solution is to approach problem from the other way. Why don’t we try to make the bacteria sensitive to already developed antibiotics once again? This is our approach. We accomplish it by engineering silencing artificial small RNAs against the resistance genes.

The graph below shows that it is possible to artificially engineer small RNA molecules to lower the resistance of Escherichia coli against the antibiotic kanamycin. Two different sRNAs, UU17 and UU37 had a significant effect compared to expression of a wild-type regulating sRNA.

Targeting resistance with sRNAs is one approach to an alleviation of the problem with antibiotic resistance, but there are several more. It has been shown that site directed mutagenesis on certain proteins which natively repress antibiotic resistance genes can create superrepressor proteins. Another possible way to lower resistance to antibiotics is to overexpress proteins that repress DNA-repair, such as the LexA protein. It might be possible to use these proteins to repress antibiotic resistance, and this is something we are actively investigating.

Our team is investigating methods to radically increase plasmid loss rate among bacteria by inducing plasmid-cutting enzymes in the bacteria. We are using TAL Effector Nucleases, a new fusion protein originating from a plant pathogen DNA binder and a FokI DNA cleavage domain

There might be even more creative solutions to the problem of antibiotic resistance. In a future perspective, it may be possible to with high selectivity engineer modular proteins targeting very specific sequences of DNA. Transcription activator-like effectors are modular proteins exhibiting exactly this function. We are planning an approach to use these proteins to cut specific DNA sequences with high specificity.

In conclusion, we have constructed several small synthetic antisense RNAs and shown that we can down-regulate resistance to kanamycin with more than 75 %. We are currently working with developing new small RNAs against other resistance genes and also combining small RNAs with targeting of gene networks described above to get a potential synergy effect when combining the different approaches.

Our approach is fundamentally based on the idea that creative synthetic biology solutions are working means to solve global problems. Efficient cooperation with teams around the world will make the SynBio society more potent to engineer new solutions to difficult problems. This is why we also want to contribute to solving common problems other iGEM-teams have. Thus, the last approach we take to improve the common toolbox of the SynBio community is to add new characterized parts. We have constructed and characterized efficient low copy BioBrick standard vectors and added new chromoproteins. The intention is that these will be used in systems by other teams having the same vision as us; using synthetic biology as means to solve the daunting problems humanity are facing, and will be facing in the future.

Challenge
The primary goal was to construct synthetic small RNAs to silence antibiotic resistance genes. This could potentially be a way to make resistant bacteria sensitive against existing antibiotics, but the problem is to design or find the ideal sRNA sequences.

Background
Spot42 is one of many non-coding RNAs in Escherichia coli. It is a small regulatory RNA that acts as one of the factors involved in the central and secondary metabolism where it regulates the switch between fermentation and respiration [2]. Spot42 contains two distinctive regions, where one is the antisense region, the part of the sRNA that interacts with other RNAs, and one is the region that recruits an RNA binding protein called Hfq.

Our goal was to engineer the native sRNA spot42 to instead target the kanamycin resistance gene AAC(6’), isolated from an ESBL plasmid from an outbreak of multiresistent bacteria in a hospital in Sweden. In theory, the sRNA with its modified antisense region would Watson-crick base pair with the complementary mRNA sequence at the 5’UTR of the antibiotic resistance gene AAC(6´), blocking ribosomal binding. This would supposedly lead to an inhibition of the translation and henceforth a silencing of the antibiotic resistance gene AAC (6´).

Earlier studies of how to design an artificial sRNA showed that there were unknown factors determining whether an sRNA would be effective in blocking translation or not. To find the optimal sRNA, a large randomised library of sRNAs was made to find sequences efficient enough to down regulate the antibiotic resistance with a combinatorial approach[1].

Constructing a randomized library of small RNAs The native Spot42 gene spf from E coli was cloned in a BioBrick plasmid, and placed in front of a synthetic constitutive promoter (J23101). Using this plasmid as template, primers binding to the Hfq binding region and the promoter with overhangs containing a randomized nucleotide sequence of 30 bp was designed (15 randomized nucleotides per primer). By running an inverse PCR on the plasmid with these primers and religating the mutagenized plasmids, a randomized library was created with a maximal theoretical size of 4^30 unique sRNA, only limited by the volume of the PCR reaction.

In order to screen for small RNAs with an antisense region hybridizing in an silencing manner to the 5’ UTR of the antibiotic resistance gene AAC (6´), the randomized sRNAs were transformed into an E coli MG1655 strain carrying a reporter system containing the native 5´UTR of AAC(6’) followed by an additional 15 codons of the coding sequence of AAC(6’) translationally fused via a linker (J18922) to the yellow fluorescent protein SYFP2 (K864100).

Since the reporter system and the sRNA library were on two different plasmids, two suitable plasmid backbones were chosen from different compatibility groups. To make the reporter system as similar to the expression levels of the natural resistance genes, a low copy origin such as pSC101 (BBa_K864001) and the sRNA library required a medium copy backbone such as p15A. Unfortunately, the low copy backbones of the pSB4X5 serie in the registry did not display the predicted behavior of a low copy plasmid, henceforth the decision to construct new plasmid backbones that could meet our requirements Read more

A randomized antisense region of thirty bases resulted in an immense library of sRNAs, where the limiting factor was the transformation efficiency of or competent cells. To be able to find promising silencing sRNAs in this vast library, a Fluorescence Activated Cell Sorter (FACSAria II from BD) was used to sort out 20 000 cells that showed a downregulation of SYFP2 from a total of 10^7 cells. By using the cell sorter function on the FACS machine the amount of false postives were dramatically reduced. This is because the FACS it makes it possible to differentiate between cells with a very low fluorescence and cells that have no fluorescence at all, non-fluorescent cells were expected to might have picked up a loss of function mutations in the SYFP gene.

The cells sorted based on lowered fluorescence were plated on selective agar plates and studied under UV light in order to screen for colonies containing a small RNA that had downregulated the SYFP2 gene. This was problematic due to radiative DNA-damage that was inflicted on the bacteria, and a substantial difference in cell growth was observed. This problem was resolved by switching to a Visi-Blue transilluminator, avoiding damage to the cells and also simplified future screening.

Clones that showed lowered expression of SYFP2 were measured for fluorescence using flow cytometry. The fluorescence levels could be distinguished with a accuracy of just a few percent.

The plasmids that contained sRNA down regulating SYFP2 were purified and transformed into DH5alpha, and then purified again to ensure pure plasmid clones free from reporter plasmids.

Finally, the isolated sRNA plasmids were transformed into a new reporter strain to validate the down regulation with flow cytometry

The reporter system together with the native spot42 has been sent as parts to the registry. This is to give future iGEM teams the possibility to repress any gene by replacing the RFP region with the 5´UTR of the gene of interest.

Delivery of constructs
Synthetic small RNAs and repressors of resistance genes need to be expressed inside the bacterial cell to be efficient, so to be used as a drug we would need a method to deliver them to as many bacterial cells as possible. Two different approaches were investigated: delivery thought M13 phage or through a conjugative plasmid.

The M13 phage is an well characterized bacteriophage that specifically targets E coli and is often used in recombinant DNA technologies. It inserts a single stranded circular DNA and hijacka the bacterial systems to replicate their own DNA to make more phages. It has been shown that it is possible to deliver synthetic DNA into a resistant E coli strain using a phage, making the host cell less antibiotic resistant. [1]

The phage approach was demonstrated by Timothy et al 2009, where they inserted proteins LexA and OmpF in the phage M13 that we have also have worked with (see gene networks for explanation of the genes LexA and OmpF).The infected cells showed a decrease in antibiotic resistance. In the article they also tested to inject engineered phages in mice infected with antibiotic resistant bacteria and eight out of ten survived instead of one out of ten when not infected with phages.

Conjugation is a process in bacteria that enables bacteria to share genetic information by spreading plasmids to each other. In E coli, conjugation is initiated when the donor bacteria develop pili that bind to the surface of the receiver bacteria. Through this pilus conjugative plasmids can be transferred to the receiver cell. It might be possible to use this functionality of conjugative plasmids to deliver our synthetic genes to resistant bacteria.

We have not only manage to clone the ompF and LexA genes, but also constructed a super-repressing mutant of MarR (see Gene networks), all proteins targeting antibiotic resistance in different ways. It is very possible that we could see a synergistic effect on the decrease of resistance if you would combine these protein based approaches with our synthetic small RNAs in a phage or conjugative plasmid.

[1]Timothy K. Lua,b and James J. Collinsb, 2009, Engineered bacteriophage targeting gene,PNAS N0.12 2009, p 4629 – 4634

We have also characterized the following five new chromoproteins from last years iGEM team:

• aeBlue
• eforRed
• cjBlue
• amilCP
• amilGFP

The new chromoproteins were originally extracted from corals; they are conjugated proteins that contain a pigmented prosthetic group. The fluorescent proteins have proven to be very efficient when used for reporter systems because of their bright fluorescence. The primary reason why we continued to characterize the chromoproteins was because we realized that there was an increasing demand amongst other iGEM teams Read more

Characteriation of promoters:
Promoters such as Plac, PlaciQ, J23-series, PLlacO, T5lac etc. have been characterized in a promoter test to see promoter strength in different situations (different strains, lacI represeed, IPTG induced etc).

Scarless deletion negative/positive selection:
By preforming λ-red the cat-SacB genes are placed on the chromosome deleting the sequence between the homologies PCRed on the end of the cat-SacB. First successful clones are selected on chloramphenicol then a second λ-red is preformed with a oligo-sequence from from just the same homologies as used before. Successful clones are selected on sucrose (SacB converts sucrose into a toxin in E.Coli).

New working low-copy backbones:
Due to a need for a low copy BioBrick plasmid in our project, we have thus devoloped a new series of BioBrick standard vectors. The new pSB4x15 backbones have a low copy pSC101 replication origin (~5 copies per cell) and ampicillin, chloramphenicol, kanamycin or spectinomycin antibiotic resistance markers. They are especially designed for Lambda Red recombineering in E coli. The backbone sequence is based on pSB3T5, but the E coli His operon terminator BBa_B0053 has been replaced with the late terminator of the Salmonellaphage P22, similar to BBa_K59200. The pSB4x15 series i brief

• Verified low copy number
• More accurate annotation
• No homologies to E coli genome that interferes with Lambda red recombineering
• Easy introduction of new resistance casettes
• Easy introduction of new orthonongal replication origins
• Smaller backbone size
• Flp recombinase target sites around the resistance casette available
• LacIq versions for tight represion available
• Thermosensitive version available